{"url_path":"/sec/tara/8-k/2026-06-29/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-073184-index.html","accession_number":"0001213900-26-073184","cik":"0001359931","ticker":"TARA","issuer_name":"Protara Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1359931/0001213900-26-073184-index.html","primary_entity_key":"0001359931","primary_entity_name":"Protara Therapeutics, Inc."},"word_count":137,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nProtara Therapeutics, Inc. (the “Company”)\nannounced that Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned from the Company to explore other opportunities,\neffective as of June 26, 2026. Dr. Nicacio's duties will be subsumed by Carla Beckham, M.D., the Company's Lead Medical Director and Head of Clinical Development, and\nwill continue under the oversight of Jacqueline Zummo, Ph.D., the Company's Chief Research & Development Officer.\n\n \n\n1 \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate: June 29, 2026\n\n \n\n \n**Protara Therapeutics, Inc.**\n\n \n \n \n\n \nBy:\n/s/ Patrick Fabbio\n\n \n \nPatrick Fabbio\n\n \n \n*Chief Financial Officer*\n\n \n\n2"}